Can We Predict Osimertinib Resistance?
There are certain indicators for patients with lung cancer who may progress on osimertinib.
There are certain characteristics that seem to have an effect on acquired resistance to osimertinib (Tagrisso) for patients with EGFR-positive non-small cell lung cancer (NSCLC), explained Niels Reinmuth, MD, PhD, head of the Thoracic Oncology Department at Asklepios Lung Clinic.
Those who progressed on the agent tended to have genetic amplifications or alterations, or changes in their signaling pathways, such as PI3k or BRAF.
While about 20 to 25% of patients can be molecularly identified, there is still work to be done for the rest of patient population.